SecBot SecBot
SECBOTREPLAY Home › Report › UTHR

UTHR · United Therapeutics reported Q2 2026 revenue of $783.3M, down 2% YoY…

UNITED THERAPEUTICS Corp · 8-K filed Aug 5, 2026 at 06:33 ET

At the news

MIXEDIMPACT 6/10

8-K filed Aug 5, 2026 at 06:33 ET

United Therapeutics reported Q2 2026 revenue of $783.3M, down 2% YoY and below the $804.6M consensus, while diluted EPS of $7.27 beat the $6.86 estimate by 5.9%. The revenue miss was driven by a 4% decline in total Tyvaso sales as Nebulized Tyvaso dropped 18% YoY, partially offset by Tyvaso DPI growth. Net income rose 8% YoY to $333.0M, benefiting from a lower effective tax rate (11% vs 24%) and the absence of a prior-year $21.7M PPE impairment. The company highlighted recent NDA submissions for ralinepag (PAH) and Nebulized Tyvaso (IPF) as key pipeline catalysts, but the top-line decline and competitive headwinds in the inhaled prostacyclin class temper the outlook.

  • Revenue decreased 2% YoY to $783.3M, missing consensus of $804.6M.
  • Diluted EPS of $7.27 beat consensus of $6.86 by 5.9%.
  • Total Tyvaso revenue fell 4% YoY to $452.6M; Nebulized Tyvaso declined 18% to $126.0M.
  • Tyvaso DPI revenue grew 4% YoY to $326.6M, with record patient starts and referrals.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access